H A Alimi, M Osundina, M Ijikoyejo, T Badmos, K O Akande, O T Oke, A A Aje, A Akere, F Fehintola, J A Otegbayo
{"title":"伊巴丹大学学院医院肝细胞癌患者的分期特异性治疗和临床结果：5年回顾","authors":"H A Alimi, M Osundina, M Ijikoyejo, T Badmos, K O Akande, O T Oke, A A Aje, A Akere, F Fehintola, J A Otegbayo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is associated with high mortality, ranking third among cancer deaths. This study aimed to spotlight the risk factors, treatment modality and clinical outcomes over a 5-year period in our hospital.</p><p><strong>Methodology: </strong>This retrospective study was done at the University College Hospital, Ibadan. All the patients with HCC diagnosed between 1st January 2019 and 31st December 2023 had their demographics, clinical information, and investigations collected. The outcome was overall survival, defined as time from diagnosis till death or lost to follow up. Data obtained was analyzed using SPSS version 20.</p><p><strong>Results: </strong>A total of 138 patients were studied, 117 males (85%) and 21 females (15%). The median age was 46 years (IQR 14). Hepatitis B Virus infection was the main risk factor, found in 102 patients (73.9%). Among males, 35% took alcohol. Three patients (2.2%) with Barcelona Clinic Liver Cancer stage A, 2 underwent surgical resection, while the other one had palliative care. Of six (4.3%) stage B patients, two had levantinib, one of which also had TACE and four had palliative care only. Ten of the sixty-three patients with stage C (45.7%) received chemotherapy, while all 64 (46.4%) in stage D received supportive care. Two (1.4%) unclassified patients received symptomatic treatment. Median survival times were 1.2 months for palliative care, 3 months for chemotherapy, and 18 months for resection (P < 0.005).</p><p><strong>Conclusion: </strong>Hepatitis B Virus was the main risk factor for HCC in our environment. Hepatic resection offered the best opportunity for survival.</p>","PeriodicalId":72221,"journal":{"name":"Annals of Ibadan postgraduate medicine","volume":"23 1","pages":"105-111"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337960/pdf/","citationCount":"0","resultStr":"{\"title\":\"STAGE-SPECIFIC TREATMENT AND CLINICAL OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CANCER AT THE UNIVERSITY COLLEGE HOSPITAL, IBADAN: A 5-YEAR REVIEW.\",\"authors\":\"H A Alimi, M Osundina, M Ijikoyejo, T Badmos, K O Akande, O T Oke, A A Aje, A Akere, F Fehintola, J A Otegbayo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is associated with high mortality, ranking third among cancer deaths. This study aimed to spotlight the risk factors, treatment modality and clinical outcomes over a 5-year period in our hospital.</p><p><strong>Methodology: </strong>This retrospective study was done at the University College Hospital, Ibadan. All the patients with HCC diagnosed between 1st January 2019 and 31st December 2023 had their demographics, clinical information, and investigations collected. The outcome was overall survival, defined as time from diagnosis till death or lost to follow up. Data obtained was analyzed using SPSS version 20.</p><p><strong>Results: </strong>A total of 138 patients were studied, 117 males (85%) and 21 females (15%). The median age was 46 years (IQR 14). Hepatitis B Virus infection was the main risk factor, found in 102 patients (73.9%). Among males, 35% took alcohol. Three patients (2.2%) with Barcelona Clinic Liver Cancer stage A, 2 underwent surgical resection, while the other one had palliative care. Of six (4.3%) stage B patients, two had levantinib, one of which also had TACE and four had palliative care only. Ten of the sixty-three patients with stage C (45.7%) received chemotherapy, while all 64 (46.4%) in stage D received supportive care. Two (1.4%) unclassified patients received symptomatic treatment. Median survival times were 1.2 months for palliative care, 3 months for chemotherapy, and 18 months for resection (P < 0.005).</p><p><strong>Conclusion: </strong>Hepatitis B Virus was the main risk factor for HCC in our environment. Hepatic resection offered the best opportunity for survival.</p>\",\"PeriodicalId\":72221,\"journal\":{\"name\":\"Annals of Ibadan postgraduate medicine\",\"volume\":\"23 1\",\"pages\":\"105-111\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337960/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Ibadan postgraduate medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Ibadan postgraduate medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景：肝细胞癌（HCC）与高死亡率相关，在癌症死亡中排名第三。本研究旨在了解我院5年的风险因素、治疗方式和临床结果。方法：本回顾性研究在伊巴丹大学学院医院进行。收集了2019年1月1日至2023年12月31日期间诊断的所有HCC患者的人口统计数据、临床信息和调查结果。结果是总生存率，定义为从诊断到死亡或失去随访的时间。所得数据使用SPSS version 20进行分析。结果：共138例患者，其中男性117例（85%），女性21例（15%）。中位年龄为46岁（IQR 14）。乙型肝炎病毒感染是主要危险因素，102例（73.9%）。在男性中，35%的人饮酒。3例（2.2%）巴塞罗那临床肝癌A、2期患者行手术切除，1例行姑息治疗。在6名（4.3%）B期患者中，2名接受了levantinib治疗，1名同时接受了TACE治疗，4名仅接受了姑息治疗。63例C期患者中有10例（45.7%）接受了化疗，而64例（46.4%）D期患者均接受了支持治疗。2例（1.4%）未分类患者接受对症治疗。姑息治疗组的中位生存时间为1.2个月，化疗组为3个月，切除组为18个月（P < 0.005）。结论：乙型肝炎病毒是我国环境中肝癌发生的主要危险因素。肝切除术为患者提供了最好的生存机会。
STAGE-SPECIFIC TREATMENT AND CLINICAL OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CANCER AT THE UNIVERSITY COLLEGE HOSPITAL, IBADAN: A 5-YEAR REVIEW.
Background: Hepatocellular carcinoma (HCC) is associated with high mortality, ranking third among cancer deaths. This study aimed to spotlight the risk factors, treatment modality and clinical outcomes over a 5-year period in our hospital.
Methodology: This retrospective study was done at the University College Hospital, Ibadan. All the patients with HCC diagnosed between 1st January 2019 and 31st December 2023 had their demographics, clinical information, and investigations collected. The outcome was overall survival, defined as time from diagnosis till death or lost to follow up. Data obtained was analyzed using SPSS version 20.
Results: A total of 138 patients were studied, 117 males (85%) and 21 females (15%). The median age was 46 years (IQR 14). Hepatitis B Virus infection was the main risk factor, found in 102 patients (73.9%). Among males, 35% took alcohol. Three patients (2.2%) with Barcelona Clinic Liver Cancer stage A, 2 underwent surgical resection, while the other one had palliative care. Of six (4.3%) stage B patients, two had levantinib, one of which also had TACE and four had palliative care only. Ten of the sixty-three patients with stage C (45.7%) received chemotherapy, while all 64 (46.4%) in stage D received supportive care. Two (1.4%) unclassified patients received symptomatic treatment. Median survival times were 1.2 months for palliative care, 3 months for chemotherapy, and 18 months for resection (P < 0.005).
Conclusion: Hepatitis B Virus was the main risk factor for HCC in our environment. Hepatic resection offered the best opportunity for survival.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
